FDA-cleared dental AI has passed FDA premarket review as a medical device intended to support clinical decisions — most often software that analyzes radiographs and surfaces possible findings for a licensed clinician to evaluate. Non-diagnostic dental AI handles tasks that fall entirely outside that device definition: documentation, visit preparation, patient communication, and workflow automation. Understanding which category a tool belongs to shapes how you evaluate it, how your staff uses it, and what liability considerations apply.

The distinction matters more than most procurement checklists acknowledge. Practices that conflate the two categories often end up either over-auditing documentation tools under a compliance lens designed for diagnostic software, or under-scrutinizing diagnostic aids that carry regulatory obligations the vendor has not surfaced clearly.

What separates FDA-cleared from non-diagnostic dental AI

FDA clearance — formally, 510(k) clearance — means a software product has been reviewed as a Class II medical device and found substantially equivalent to a legally marketed predicate. For dental AI, clearance typically applies to software that renders or assists a clinical interpretation: identifying potential pathology on a radiograph and surfacing it for a clinician’s evaluation. Cleared products carry specific indications for use, and claims made outside those indications are not covered by the clearance.

What FDA clearance does — and does not — mean in practice:

• Cleared means the FDA found the product substantially equivalent to a predicate, not that it has been proven superior to unaided clinical judgment.
• Clearance is indication-specific: a tool cleared for interproximal caries detection on bitewing radiographs may not be cleared for periapical analysis or alveolar bone-level assessment.
• Cleared tools still require a licensed clinician to make all final diagnostic and treatment decisions; the AI assists, it does not decide.
• Professional liability is not eliminated by clearance when a clinician over-relies on AI output or uses a tool outside its stated indication.
• Software updates that materially alter intended use may require new regulatory filings to maintain clearance status.

Buyers frequently assume that “dental AI” as a category is either entirely regulated or entirely unregulated. The reality is a mixed landscape. Many tools active in dental practices today were never submitted to the FDA because they were never designed to support clinical diagnosis — they handle documentation, scheduling logic, and practice operations instead.

Where non-diagnostic AI fits in your workflow

Non-diagnostic dental AI covers territory entirely outside clinical interpretation: capturing and structuring encounters, automating chart documentation, strengthening records before payer submission, and managing patient communication at scale. These products are evaluated on fundamentally different criteria than cleared diagnostic devices — transcription accuracy, EHR compatibility, documentation completeness, and measurable return on chair time and revenue.

Rebrief’s charting platform is built almost entirely in this category. The Autonomous Charting Agent uses AmbientVision™ to capture the operatory encounter in real time and structure it into a defensible chart note — without rendering or influencing a clinical diagnosis. PracticeShield™ runs a chart-audit and denial-defense layer, checking documentation against payer requirements before a claim is submitted. Together, these agents address the 4.4 hours per week that documentation consumes per clinician on average — time that currently comes out of patient care or the end of the clinical day.

A note on Rebrief Vision: Rebrief Vision is an AI-powered radiograph annotation tool designed for case presentations and patient education. It helps clinicians visualize findings they have already identified, for treatment-plan discussion with patients. Rebrief Vision is for case presentation and patient education only; it is not FDA-cleared and is not a diagnostic device.

How to evaluate any dental AI tool before you sign

Whether a product carries FDA clearance or operates as a non-diagnostic workflow agent, a consistent evaluation framework protects your practice and simplifies compliance conversations with department leadership, institutional review bodies, and payer auditors. Before committing to any dental AI vendor, work through these questions:

• Intended use: What does the vendor explicitly say the product does? Is the described clinical workflow consistent with that stated use?
• Regulatory status: Is it FDA-cleared, and for which specific indication? Or does the vendor explicitly disclaim diagnostic intent in writing?
• EHR integration: Does it connect natively to your system — Epic, Dentrix, Curve Dental, Open Dental, Patterson Eaglesoft, and others — or does it create a parallel workflow your staff must manage separately?
• Liability framing: Who bears responsibility for a clinical decision influenced by the tool’s output, and what does the vendor’s contract say about that allocation?
• Documentation output quality: For non-diagnostic tools specifically, does the structured output meet payer audit standards and support denial defense if a claim is challenged?

Practices that approach this evaluation with discipline tend to deploy both categories deliberately: a cleared diagnostic aid where clinical decision support is the explicit goal, and a workflow platform like Rebrief where documentation quality, chair-time recovery, and payer outcomes are the measures that matter. See Rebrief’s pricing and tiers for how the platform structures access across Evidence, Professional, and Enterprise configurations.

Want a longer answer? The nuances of dental AI regulation — what constitutes a device under the FDA’s software framework, how indications for use are scoped and enforced, and how documentation-only tools interact with your compliance program — are worth a direct conversation. Reserve a demo and we will walk through where Rebrief sits in your workflow and what the regulatory picture looks like for the tools you are currently using or evaluating.